Issues
-
Cover Image
Cover Image
An inducible form of the terminal PGE2 synthase, mPGES-1, is elevated in colorectal cancer (CRC), often in association with COX-2. mPGES-1 has been suggested as an alternative target to COX-2 for CRC prevention, with potentially lower cardiovascular toxicity. The efficacy of targeting mPGES-1 was examined in mouse genetic and carcinogen-induced models. Genetic deletion of mPGES-1 significantly suppressed the growth of Apc-initiated intestinal tumors, and the formation of carcinogen-induced preneoplastic aberrant crypt foci (ACF) in the colon. Interestingly, nuclear translocation of Β-catenin in ACF was blocked in mPGES-1 null mice, indicating that the Wnt pathway mediates the tumor-promoting action of mPGES-1 and PGE2. These data support the feasibility of targeting mPGES-1 for CRC prevention, which may be a safer approach relative to traditional NSAIDs and selective COX-2 inhibitors. For details, see the article by Nakanishi and colleagues on page 3251 of this issue. - PDF Icon PDF LinkTable of Contents
Cancer Research
Table of Contents
Reviews
Priority Report
Molecular Biology, Pathobiology, and Genetics
Protein Kinase A Effects of an Expressed PRKAR1A Mutation Associated with Aggressive Tumors
Epigenetic Modification of CCAAT/Enhancer Binding Protein α Expression in Acute Myeloid Leukemia
Cell, Tumor, and Stem Cell Biology
Nutlin-3a Activates p53 to Both Down-regulate Inhibitor of Growth 2 and Up-regulate mir-34a, mir-34b, and mir-34c Expression, and Induce Senescence
Pituitary Tumor-Transforming 1 Increases Cell Motility and Promotes Lymph Node Metastasis in Esophageal Squamous Cell Carcinoma
Experimental Therapeutics, Molecular Targets, and Chemical Biology
Genomic Alterations of Anaplastic Lymphoma Kinase May Sensitize Tumors to Anaplastic Lymphoma Kinase Inhibitors
ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor
Immunology
Endocrinology
Epidemiology
Prevention
Corrections
Editor’s Note
Journal Archive
Cancer Research
(1941-Present; volumes 1-current)Published twice monthly since 1987. From 1941-1986, published monthly.
(ISSN 0008-5472)
The American Journal of Cancer
(1931-1940; volumes 15-40)Published quarterly in 1931, bimonthly in 1932, and monthly from 1933 to 1940. The journal changed title to Cancer Research in 1941.
(ISSN 0099-7374)
The Journal of Cancer Research
(1916-1930); volumes 1-14)Published quarterly from 1916 through 1930 (publication was suspended from November 1922 to March 1924). The journal changed title to The American Journal of Cancer in 1931.
(ISSN 0099-7013)
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale within the United States of Bavencio® (avelumab), a pharmaceutical owned by Merck. If any resulting funds are received, they would not be used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.